New treatments in type 2 diabetes: a focus on the incretin-based therapies.
about
Glucagon-like peptide analogues for type 2 diabetes mellitusCardiovascular safety of anti-diabetic drugsA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsLack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicityGlucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysisEffects of exenatide in a morbidly obese patient with type 2 diabetesThe evolving place of incretin-based therapies in type 2 diabetesFurther improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.Emerging treatment options for type 2 diabetesGender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experienceNovel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the ratDPP-4 inhibitors in clinical practice.Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options.The efficacy and safety of liraglutide.Linagliptin: a review of its use in the management of type 2 diabetes mellitus.Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Walnuts (Juglans regia) Chemical Composition and Research in Human Health.Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats
P2860
Q24235918-1DA5FB7B-2157-4339-8E14-D553DB641DF6Q26741082-AC7FCB54-E4A3-4D1D-A46D-4FBB6D324A0AQ26796417-186E6255-AD83-4ED7-B8AF-8BE3781B8706Q28740948-A545265D-B03A-4487-B409-549F5E35E60FQ30249371-AB1E6E3A-3D57-451D-B4C2-D4DA061641F0Q31114603-B133F362-3FA5-4280-BBAE-895CBF994F03Q33521451-0D6C5808-0C0D-4F86-A535-38D5F17ED19CQ33712562-1234AA59-969A-4F26-B631-74B0FDDC2B90Q33767049-39C9760E-509A-470B-8334-C9C4CD9BFFCDQ33785151-4F2B77B2-83A2-4E91-AFA9-86701B8CB99EQ33866808-1D6C2CE7-CDE0-43F5-AED9-EFFB907C2C48Q33932718-8584C030-607A-4AF6-8CEB-2828AD0D6424Q34381281-4813E65B-F94D-44A4-87F4-8D3BE15D393EQ36766081-403626CC-8A6F-419B-9B65-C8ADD635AF7AQ37367934-D61F8EB4-EC78-4096-967B-314969F0A314Q37638984-506E6C20-3BD4-4008-BF44-3339BF9D6CCFQ37762321-62332C3A-D406-4B1D-B648-CE280F22EB96Q37939660-5ED5B113-0389-4B35-9E1E-9B62E3291366Q38036742-5D12F44C-6480-4239-B492-55D5C9CD886DQ38077226-9109E423-CA9D-47B2-9E81-7589EBB765EFQ38177173-95C641AC-257B-4A76-A43F-9566BD70405AQ38369343-9C076116-D5A0-4592-B508-AC1C9F907349Q39276306-3F508FBE-1E97-437A-AE15-D79859C17D2F
P2860
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@en
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@nl
type
label
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@en
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@nl
prefLabel
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@en
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@nl
P1476
New treatments in type 2 diabetes: a focus on the incretin-based therapies.
@en
P2093
Anthony H Barnett
P304
P356
10.1111/J.1365-2265.2008.03396.X
P577
2008-09-02T00:00:00Z